Gonadotrophin Releasing Hormone Agonist for Dual Trigger in in Vitro Fertilization and for Luteal Phase Support in Frozen-thawed Embryo Transfer
Who is this study for? Women undergoing in vitro fertilization
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 42
Healthy Volunteers: f
View:
⁃ \- Women aged \<43 years at the time of IVF treatment
• Women aged \<43 years at the time of IVF treatment
• Replacing early cleavage embryos or blastocysts after thawing
• FET in natural cycles
Locations
Other Locations
China
Department of Obstetrics and Gynaecology
RECRUITING
Hong Kong
Contact Information
Primary
Ernest HY Ng, MD
nghye@hku.hk
852-28553400
Time Frame
Start Date: 2019-09-01
Estimated Completion Date: 2025-03-30
Participants
Target number of participants: 784
Treatments
Active_comparator: IVF: dual trigger
When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
Placebo_comparator: IVF: hCG trigger
When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
Active_comparator: FET: agonist
On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
Placebo_comparator: FET: control
On the day of FET, normal saline will be injected subcutaneously.
Related Therapeutic Areas
Sponsors
Leads: The University of Hong Kong